Affordability of drugs used in oncology health care
作者： Stefan Sleijfer , Jaap Verweij
DOI: 10.1038/NRCLINONC.2016.77
关键词:
摘要: The rapidly rising costs of cancer care, driven in particular by the high prices new drugs, are increasingly challenging health-care systems across world. To ensure accessibility to novel antitumour paradigms needed at several levels, not only economically, but also terms research and study designs.
nature.com
sci-hub.se 参考文章(7)
Nick Beije, Agnes Jager, Stefan Sleijfer, Circulating tumor cell enumeration by the CellSearch system: The clinician’s guide to breast cancer treatment? Cancer Treatment Reviews. ,vol. 41, pp. 144- 150 ,(2015) , 10.1016/J.CTRV.2014.12.008
Stefan Sleijfer, Jan Bogaerts, Lillian L. Siu, Designing Transformative Clinical Trials in the Cancer Genome Era Journal of Clinical Oncology. ,vol. 31, pp. 1834- 1841 ,(2013) , 10.1200/JCO.2012.45.3639
Marie-Therese Sickinger, Bastian von Tresckow, Carsten Kobe, Andreas Engert, Peter Borchmann, Nicole Skoetz, Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma Cochrane Database of Systematic Reviews. ,vol. 1, ,(2015) , 10.1002/14651858.CD010533.PUB2
N.I. Cherny, R. Sullivan, U. Dafni, J.M. Kerst, A. Sobrero, C. Zielinski, E.G.E. de Vries, M.J. Piccart, A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Annals of Oncology. ,vol. 26, pp. 1547- 1573 ,(2015) , 10.1093/ANNONC/MDV249
Diwakar Davar, Mark A. Socinski, Sanja Dacic, Timothy F. Burns, Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma Experimental hematology & oncology. ,vol. 4, pp. 34- 34 ,(2015) , 10.1186/S40164-015-0029-7
Pieter van Eijsden, Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly BMJ. ,vol. 351, ,(2015) , 10.1136/BMJ.H6778
Wim H van Harten, Anke Wind, Paolo de Paoli, Mahasti Saghatchian, Simon Oberst, Actual costs of cancer drugs in 15 European countries. Lancet Oncology. ,vol. 17, pp. 18- 20 ,(2016) , 10.1016/S1470-2045(15)00486-6